Karachi: Abbott Laboratories (Pakistan) Limited announced its financial results for the first quarter ending March 31, 2025, highlighting a robust increase in net profit despite a noticeable decline in export sales. The Board of Directors approved the financial outcomes during a virtual meeting held on Monday, April 28, 2025.

The company reported net sales of 17.35 billion rupees, up from 16.03 billion rupees in the same period last year. This growth was primarily driven by a substantial rise in local sales, which reached 16.86 billion rupees compared to 15.24 billion rupees in the previous year. However, export sales fell to 489.96 million rupees from 790.20 million rupees, reflecting a challenging international market environment.

Gross profit for the quarter rose significantly to 5.84 billion rupees from 4.45 billion rupees, indicating effective cost management strategies with the cost of sales slightly decreasing to 11.50 billion rupees from 11.58 billion rupees. Selling and distribution expenses increased to 2.72 billion rupees from 2.40 billion rupees, and administrative expenses rose to 303.02 million rupees from 268.74 million rupees. Other charges also saw an increase to 321.82 million rupees from 177.28 million rupees, while other income slightly increased to 260.10 million rupees from 255.54 million rupees.

According to information available from the Pakistan Stock Exchange (PSX), Abbott’s profit before taxes stood at 2.75 billion rupees, up from 1.86 billion rupees in the previous year. After accounting for tax differentials and final taxes, the company reported a net profit of 1.60 billion rupees, an increase from 1.52 billion rupees in the previous year. The basic and diluted earnings per share improved to 16.34 rupees from 15.51 rupees.

The company’s balance sheet as of March 31, 2025, showed total assets of 39.35 billion rupees, up from 37.65 billion rupees as of December 31, 2024. Non-current assets slightly increased to 14.56 billion rupees, while current assets rose to 24.78 billion rupees from 23.26 billion rupees. Total equity improved to 24.42 billion rupees from 23.72 billion rupees, reflecting a healthy financial position.

Cash flow from operating activities marked a positive inflow of 803.72 million rupees, a significant turnaround from the outflow of 250.55 million rupees in the previous year. However, cash flows from investing activities resulted in an outflow of 387.62 million rupees, and financing activities led to an outflow of 4.32 million rupees.

The report indicates that Abbott Laboratories (Pakistan) Limited continues to maintain a strong financial position despite external challenges, with a focus on enhancing local market performance while navigating export market difficulties. The pharmaceutical sector remains a key area of focus for the company in the designated market category.